Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Abstract

In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849 .).

Keywords

MeSH Terms

Affiliated Institutions

• Goethe University Frankfurt DE
• Université Paris Cité FR
• University of Utah US
• Royal Children's Hospital AU
• University of Milano-Bicocca IT
• C. S. Mott Children's Hospital US
• St Anna Children's Hospital AT
• Emory University US
• Hospital Sant Joan de Déu Barcelona ES
• University of Pennsylvania US
• Center for Cancer and Blood Disorders US
• Ghent University Hospital BE
• Hospital for Sick Children CA
• Centre Hospitalier Universitaire Sainte-Justine CA
• Children's Hospital of Philadelphia US
• Oslo University Hospital
• Kyoto University JP
• Délégation Paris 7 FR
• Novartis Institutes for BioMedical Research
• University of Minnesota US
• Duke Medical Center US
• Stanford University US
• Novartis (Switzerland) CH
• Children's Hospital of Los Angeles US
• Université de Montréal CA
• Children's Mercy Hospital US
• University Hospital Frankfurt DE
• Oregon Health & Science University US

Related Publications